Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 69

Sort by

Sort Order Select

Journal Articles

Optical Genome Mapping Combined with High-Throughput Sequencing Is Effective for the Diagnostic and Prognostic Genomic Classification of Acute Myeloid Leukemia and Myelodysplastic Neoplasms

Yannick LE Bris, Romain Madeuf, Catherine Godon, Olivier Pichon, Pierre Peterlin, Alice Garnier, Patrice Chevallier, Simon Bouzy, Marion Eveillard, Marie-Christine Béné, Olivier Theisen, Faeseh vasheghani Farahani

Blood (2023) 142 (Supplement 1): 6051.

https://doi.org/10.1182/blood-2023-188581

Published: 2023

Journal Articles

Sequential Conditioning Regimen with Thiotepa, Clofarabine and Busulfan (TEC/CloB2A2) and Post-Transplant Cyclophosphamide in Adults with Refractory AML: A Retrospective Monocentric Study

Amandine Le Bourgeois, Alice Garnier, Pierre Peterlin, Maxime Jullien, Chloe Antier, Thierry Guillaume, Patrice Chevallier

Blood (2023) 142 (Supplement 1): 6963.

https://doi.org/10.1182/blood-2023-179861

Published: 2023

Journal Articles

Combination Chemotherapy in Patients with Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCN): First Results of a Prospective French Trial (LpDessai)

Blood (2023) 142 (Supplement 1): 1516.

https://doi.org/10.1182/blood-2023-173379

Published: 2023

Journal Articles

Fms-like Tyrosine Kinase 3 Ligand Kinetic Profile Is the Strongest Factor Predicting Refractoriness after Induction and Event-Free Survival in Adults with AML: A Filo Prospective Multicentric Study

Blood (2023) 142 (Supplement 1): 975.

https://doi.org/10.1182/blood-2023-173518

Published: 2023

Journal Articles

A Phase 2 Study of Ponatinib for Prevention of Relapse after Allotransplantation in FLT3-ITD + AML Patients : The Ponallo Trial

Patrice Chevallier, Anne Thiebaut, Sylvie François, Sylvain Chantepie, Marie Thérèse Rubio, Hélène Labussière-Wallet, Eolia Brissot, Natacha Maillard, Anne Huynh, Valerie Coiteux, Alice Garnier, Amandine Le Bourgeois, Pierre Peterlin, Thierry Guillaume

Blood (2023) 142 (Supplement 1): 4957.

https://doi.org/10.1182/blood-2023-179734

Published: 2023

Journal Articles

Azacitidine for Patients with Vexas Syndrome: Data from the French Vexas Registry

Thibault Comont, Olivier Kosmider, Mael Heiblig, Benjamin Terrier, Didier Bouscary, Guillaume Le Guenno, Roderau Outh, Maxime Samson, Achille Aouba, Estibaliz Lazarro, Odile Rauzy, Lucie Rigolot, Pierre Peterlin, Alexandre Maria, Edouard Flammarion, Alice Garnier, Benoit De Renzis, Shanti Natarajan, Benjamin Carpentier, Marielle Roux-Sauvat, Jose Torregrosa, Fabienne Closs-Prophette, Julien Rossignol, Nicolas Schleinitz, Celine Dieval, Jonahan Broner, Marie-Pierre Gourin, Gaetan Sauvetre, Benoit Faucher, Julien Vinit, Sylvie Grosleron, Alexis Mathian, Louis Terriou, Cyrille Coustal, Philippe Guilpain, Paola Marianetti-Guingel, Holy Bezanahary, Norbert Vey, Bilal Mohty, Thomas Moulinet, Vincent Grobost, Sophie Dimicoli, Benoit Suzon, Antoinette Perlat, Pierre Hirsh, Lise Larcher, Lin Pierre Zhao, Sophie Georgin-Lavialle, Arsene Mekinian, Pierre Fenaux, Vincent Jachiet, French VEXAS study group, Minhemon French Network of immune disorders associated with hemopathies, GFM Groupe Francophone des Myélodysplasies

Blood (2023) 142 (Supplement 1): 4604.

https://doi.org/10.1182/blood-2023-178125

Published: 2023

Journal Articles

Pre-Graft Vaccination or Infection Do Not Provide More Protection Against COVID-19 Infections in Post-Graft Vaccinated Recipients of Allogeneic Stem Cell Transplantation

Valentin Letailleur, Amandine Le Bourgeois, Thierry Guillaume, Alice Garnier, Pierre Peterlin, Maxime Jullien, Chloe Antier, Marie-Christine Béné, Patrice Chevallier

Blood (2023) 142 (Supplement 1): 4941.

https://doi.org/10.1182/blood-2023-179991

Published: 2023

Journal Articles

Comparison of Two Reduced Intensity Conditioning Regimens (Baltimore with Clofarabine vs Thiotepa-Busulfan-Fludarabine) in Adults Receiving Peripheral Blood Stem Cell Haploidentical Transplantation for Myeloid Malignancies: A Retrospective Study of the SFGM-TC

Blood (2023) 142 (Supplement 1): 3530.

https://doi.org/10.1182/blood-2023-180581

Published: 2023

Journal Articles

A Phase II Study of Single Agent Aspacytarabine (BST-236) in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Higher Risk Myelodysplastic Syndromes (R/R HR MDS)

Marie Anne Hospital, Thomas Cluzeau, Alice Garnier, Giovanni Marconi, Emmanuelle Tavernier, Sylvain Thepot, Aspasia Stamatoullas, Cristina Papayannidis, Sophie Park, Noemie Bigot, Lamya AIT SI Selmi, Fatiha Chermat, Sylvie Chevret, Pierre Fenaux

Blood (2023) 142 (Supplement 1): 2923.

https://doi.org/10.1182/blood-2023-185609

Published: 2023

Journal Articles

Pre-Graft Immune Status Predicts Survivals and Relapse in Adults Receiving Matched Peripheral Blood Stem Cell Allotransplants for Myeloid Malignancies

Maxime Jullien, Baptiste Le Calvez, Amandine Le Bourgeois, Thierry Guillaume, Pierre Peterlin, Alice Garnier, Patrice Chevallier

Blood (2023) 142 (Supplement 1): 3622.

https://doi.org/10.1182/blood-2023-189241

Published: 2023

Journal Articles

Deep Learning Based Blood Abnormalities Detection As a Tool for Vexas Syndrome Screening

Blood (2023) 142 (Supplement 1): 3648.

https://doi.org/10.1182/blood-2023-186874

Published: 2023

Journal Articles

Dosage, Safety and Efficacy of Posaconazole As Primary Antifungal Prophylaxis in High-Risk Recipients of Allogeneic Stem Cell Transplantation

Valentin Letailleur, Maxime Jullien, Pierre Peterlin, Alice Garnier, Thomas Gastinne, Matthieu Grégoire, Florent Morio, Thierry Guillaume, Marie C Bene, Patrice Chevallier, Amandine Le Bourgeois

Blood (2022) 140 (Supplement 1): 12859–12860.

https://doi.org/10.1182/blood-2022-163413

Published: 2022

Journal Articles

Artificial Intelligence Using Multimodal Data for Myelodysplastic Syndrome Screening

Cedric De almeida Braga, Maxence Bauvais, Maxence Dominici, Alice Garnier, Pierre Peterlin, Camille Debord, Soraya Wuillème, Olivier Theisen, Catherine Godon, Simon Bouzy, Yannick Le Bris, Marie C Bene, Patrice Chevallier, Nicolas Normand, Marion Eveillard

Blood (2022) 140 (Supplement 1): 9800–9801.

https://doi.org/10.1182/blood-2022-166979

Published: 2022

Journal Articles

Addition of ATG to Clofarabine-Based Reduced Intensity Conditioning Regimen with PBSC and Ptcy in Adults with Myeloid Malignancies

Maxime Jullien, Amandine Le Bourgeois, Pierre Peterlin, Alice Garnier, Thierry Guillaume, Marie C Béné, Patrice Chevallier

Blood (2022) 140 (Supplement 1): 10451–10452.

https://doi.org/10.1182/blood-2022-167198

Published: 2022

Journal Articles

High-Risk Cytokine Profiles Predict Lower Survivals in AML after Allotransplantation

Pierre Peterlin, Joelle Gaschet, Maxime Jullien, Thierry Guillaume, Alice Garnier, Amandine Le Bourgeois, Michel Cherel, Marie C Bene, Patrice Chevallier

Blood (2022) 140 (Supplement 1): 12906–12907.

https://doi.org/10.1182/blood-2022-165348

Published: 2022

Journal Articles

Efficacy of Anti-Sars-Cov-2 mRNA Vaccines in Adults with Severe Acquired Aplastic Anemia with or without Allograft

Alice Garnier, Amandine Le Bourgeois, Thierry Guillaume, Pierre Peterlin, Maxime Jullien, Marianne Coste-Burel, Marie C Bene, Patrice Chevallier

Blood (2022) 140 (Supplement 1): 2941–2942.

https://doi.org/10.1182/blood-2022-164807

Published: 2022

Journal Articles

Higher Proportions of Monocytic-Myeloid-Derived Suppressive Cells (mMDSC) before Allotransplant Predict Relapse in Acute Leukemia Patients

Pierre Peterlin, Marie C Bene, Maxime Jullien, Thierry Guillaume, Amandine Le Bourgeois, Alice Garnier, Camille Debord, Marion Eveillard, Patrice Chevallier

Blood (2022) 140 (Supplement 1): 7682–7683.

https://doi.org/10.1182/blood-2022-158673

Published: 2022

Journal Articles

Sars-Cov-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Transplant Recipients

Beatrice Clemenceau, Amandine Le Bourgeois, Thierry Guillaume, Marianne Coste-Burel, Pierre Peterlin, Alice Garnier, Maxime Jullien, Jocelyn Ollier, Marie C. Bene, Patrice Chevallier

Blood (2022) 140 (Supplement 1): 4780–4781.

https://doi.org/10.1182/blood-2022-163177

Published: 2022

Journal Articles

Early In Vivo Generation of Vγ9Vδ2 T Cells after Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide: A Monocentric Phase 1 Study

Maxime Jullien, Thierry Guillaume, Amandine Le Bourgeois, Pierre Peterlin, Alice Garnier, Marion Eveillard, Marie C Béné, Patrice Chevallier

Blood (2022) 140 (Supplement 1): 2115–2116.

https://doi.org/10.1182/blood-2022-166960

Published: 2022

Journal Articles

Vexas Syndrome: A Complex Necessarily Integrated Diagnosis That Can Benefit from the Help of Deep Learning

Cedric De almeida Braga, Camille Richard, Baptiste Le Calvez, Patrice Chevallier, Simon Bouzy, Yannick Le Bris, Alice Garnier, Pierre Peterlin, Marie C Béné, Nicolas Normand, Marion Eveillard

Blood (2022) 140 (Supplement 1): 13025–13026.

https://doi.org/10.1182/blood-2022-169059

Published: 2022

NARROW

Optical Genome Mapping Combined with High-Throughput Sequencing Is Effective for the Diagnostic and Prognostic Genomic Classification of Acute Myeloid Leukemia and Myelodysplastic Neoplasms

Sequential Conditioning Regimen with Thiotepa, Clofarabine and Busulfan (TEC/CloB2A2) and Post-Transplant Cyclophosphamide in Adults with Refractory AML: A Retrospective Monocentric Study

Combination Chemotherapy in Patients with Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCN): First Results of a Prospective French Trial (LpDessai)

Fms-like Tyrosine Kinase 3 Ligand Kinetic Profile Is the Strongest Factor Predicting Refractoriness after Induction and Event-Free Survival in Adults with AML: A Filo Prospective Multicentric Study

A Phase 2 Study of Ponatinib for Prevention of Relapse after Allotransplantation in FLT3-ITD + AML Patients : The Ponallo Trial

Azacitidine for Patients with Vexas Syndrome: Data from the French Vexas Registry

Pre-Graft Vaccination or Infection Do Not Provide More Protection Against COVID-19 Infections in Post-Graft Vaccinated Recipients of Allogeneic Stem Cell Transplantation

Comparison of Two Reduced Intensity Conditioning Regimens (Baltimore with Clofarabine vs Thiotepa-Busulfan-Fludarabine) in Adults Receiving Peripheral Blood Stem Cell Haploidentical Transplantation for Myeloid Malignancies: A Retrospective Study of the SFGM-TC

A Phase II Study of Single Agent Aspacytarabine (BST-236) in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Higher Risk Myelodysplastic Syndromes (R/R HR MDS)

Pre-Graft Immune Status Predicts Survivals and Relapse in Adults Receiving Matched Peripheral Blood Stem Cell Allotransplants for Myeloid Malignancies

Deep Learning Based Blood Abnormalities Detection As a Tool for Vexas Syndrome Screening

Dosage, Safety and Efficacy of Posaconazole As Primary Antifungal Prophylaxis in High-Risk Recipients of Allogeneic Stem Cell Transplantation

Artificial Intelligence Using Multimodal Data for Myelodysplastic Syndrome Screening

Addition of ATG to Clofarabine-Based Reduced Intensity Conditioning Regimen with PBSC and Ptcy in Adults with Myeloid Malignancies

High-Risk Cytokine Profiles Predict Lower Survivals in AML after Allotransplantation

Efficacy of Anti-Sars-Cov-2 mRNA Vaccines in Adults with Severe Acquired Aplastic Anemia with or without Allograft

Higher Proportions of Monocytic-Myeloid-Derived Suppressive Cells (mMDSC) before Allotransplant Predict Relapse in Acute Leukemia Patients

Sars-Cov-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Transplant Recipients

Early In Vivo Generation of Vγ9Vδ2 T Cells after Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide: A Monocentric Phase 1 Study

Vexas Syndrome: A Complex Necessarily Integrated Diagnosis That Can Benefit from the Help of Deep Learning

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only